PGS on Blastocysts From Vitrified and Fresh Oocytes (PGSvitfreov)

Unità di Medicina della Riproduzione, Italy

Status: Completed

Conditions: Increase the Number of Blastocyst to Biopsy for Preimplantation Genetic Testing

Treatments: Other: chromosomal status of blastocysts from fresh and vitrified/warmed oocytes

Study type: Observational

Funder types: Other

Identifiers

NCT02820415

Trial1

Details and patient eligibility

About

Oocyte accumulation by vitrification is a valid strategy to increase the number of available embryos for biopsy and the number of viable euploid embryos to transfer after preimplantation genetic testing.

Full description

In the present study, the investigators considered the hypothesis to accumulate vitrified oocytes with a view to increasing the number of oocytes for micro-injection and consequently the number of blastocyst to diagnose for patients with normal ovarian reserve and candidate for PGT. The partecipants were proposed to undergo several cycles of ovarian stimulation. In the first cycles, mature (metaphase II) oocytes were vitrified and consequently accumulated. In the last cycle, the freshly produced mature oocytes and the previously accumulated ones were micro-injected together with the same partner's semen sample. PGT was performed on blastocysts produced from the two sources of oocytes. The comprehensive chromosomal analysis of biopsied trophectoderm cells was performed using NGS technology. The number of available euploid blastocyst and the proportion of euploid/aneuploidy embryos from fresh and vitrified/warmed oocytes were compared. In conclusion the investigators evaluated the efficacy of oocyte accumulation by vitrification in increasing the number of available embryos for biopsy and the number of viable euploid embryos to transfer after PGT.

Enrollment: 60 patients

Sex: Female

Ages: 28 to 43 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• infertile women
• normal ovarian reserve
• with repeated implantation failure or reccurent miscarriage
• undergoing ICSI and asking to know the state of health of the embryos prior to embryo transfer

Trial design

60 participants in 1 patient group

infertile couples undergoing ICSI for PGS/PGT

Description:

patients aged between 29.0 and 42.3 years, with basal FSH on day 3 between 2.9 and 12.0 IU/l. Undergoing 36 patients for RIF or RM. In each couple, the two partners had a normal karyotype. The patients underwent one to two cycles of ovarian stimulation to vitrify and accumulate oocytes and a last (second or third) cycle of ovarian stimulation. Ovarian stimulation was performed by the administration of recombinant FSH and LH (Gonal-F and Luveris: Merck-Serono, London, UK or Puregon, MSD, Franklin Lakes, USA) from cycle day 3 and luteal gonadotrophin-releasing hormone antagonist flexible schema (Cetrotide : Merck-Serono, London, UK).

Treatment:

Other: chromosomal status of blastocysts from fresh and vitrified/warmed oocytes